Niagen Bioscience, Inc. (NAGE) News
Track canonical SquawkNews coverage tagged to NAGE, Niagen Bioscience, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 18 indexed stories across 13 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
NAGE - Newly Published Preclinical Study Demonstrates CD38 as a Driver of Age-Related NAD+ Decline, Older Mothers Have Lower NAD+ Levels in Placental Tissue, and NAD+ Restoration with Nicotinamide Riboside (NR) Improves Pregnancy Outcomes
NAGE - Newly Published Preclinical Study Demonstrates CD38 as a Driver of Age-Related NAD+ Decline, Older Mothers Have Lower NAD+ Levels in Placental Tissue, and NAD+ Restoration with Nicotinamide Riboside (NR) Improves
NEWS | Sep 21, 2026, 12:42 PM UTC
L
NAGE - Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth
NAGE - Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth
NEWS | Sep 17, 2026, 12:33 PM UTC
L
NAGE - Niagen Bioscience to Present at Canaccord Genuity’s Well Summit
NAGE - Niagen Bioscience to Present at Canaccord Genuity’s Well Summit
EQUITY | Sep 10, 2026, 12:32 PM UTC
L
Niagen Bioscience to present at Canaccord Genuity’s Well Summit
Niagen Bioscience said CEO Rob Fried and CFO Ozan Pamir will participate in Canaccord Genuity’s Well Summit.
EQUITY | Sep 10, 2026, 12:32 PM UTC
L
NAGE - Niagen Bioscience to Present at Longevity Investors Conference
NAGE - Niagen Bioscience to Present at Longevity Investors Conference
EQUITY | Sep 02, 2026, 12:35 PM UTC
L
Niagen Bioscience management to present at Longevity Investors Conference
Niagen Bioscience, Inc. (NAGE) said senior management will participate in the Longevity Investors Conference from September 14 to 17, 2026, in Gstaad.
EQUITY | Sep 02, 2026, 12:32 PM UTC
L
NAGE: Strong growth, innovation, and clinical progress position the company as a leader in NAD therapeutics
NAGE: Strong growth, innovation, and clinical progress position the company as a leader in NAD therapeutics
EQUITY | Aug 27, 2026, 09:22 PM UTC
L
NAGE: Strong financials and innovation in NAD therapies drive growth and clinical progress
NAGE: Strong financials and innovation in NAD therapies drive growth and clinical progress
EQUITY | Aug 27, 2026, 08:44 PM UTC
L
NAGE - Niagen Bioscience to Present at Nasdaq X LD Micro Inaugural SF Summit
NAGE - Niagen Bioscience to Present at Nasdaq X LD Micro Inaugural SF Summit
EQUITY | Aug 26, 2026, 12:35 PM UTC
L
Niagen Bioscience to present at Nasdaq X LD Micro SF summit
Niagen Bioscience says it will present at the Nasdaq X LD Micro inaugural SF summit.
EQUITY | Aug 26, 2026, 12:32 PM UTC
M
Niagen Bioscience expands Tru Niagen retail footprint with GNC, Sam's Club
Niagen Bioscience says it is expanding Tru Niagen's retail footprint through GNC and Sam's Club.
EQUITY | Aug 20, 2026, 12:41 PM UTC
L
NAGE to Present at Midwest IDEAS Conference
NAGE is presenting at the 17th Annual Midwest IDEAS Investor Conference
EQUITY | Aug 12, 2026, 12:33 PM UTC
L
NAGE - Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results
NAGE - Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results
EARNINGS | Aug 04, 2026, 08:12 PM UTC
L
Niagen Bioscience Widens FY2026 Sales Guidance of $138.982M-$145.299M vs $141.072M Est
Niagen Bioscience (NASDAQ: NAGE ) widens FY2026 sales outlook from $138.982 million-$145.299 million to $138.982 million-$145.299 million vs $141.072 million estimate.
EARNINGS | Aug 04, 2026, 08:06 PM UTC
M
NAGE Selects Evotec For NB4168 Development
NAGE partners with Evotec for preclinical development
EQUITY | Aug 03, 2026, 12:41 PM UTC
L
NAGE - Niagen Bioscience to Present at Canaccord Genuity’s 46th Annual Growth Conference
NAGE - Niagen Bioscience to Present at Canaccord Genuity’s 46th Annual Growth Conference
EQUITY | Jul 27, 2026, 12:34 PM UTC
L
Niagen Bioscience's NB4168 Gets US FDA Rare Pediatric Disease Tag for Ataxia Telangiectasia
() -- Niagen Bioscience (NAGE) has received rare pediatric disease designation from the US Food and Drug Administration for NB4168 in treating ataxia telangiectasia, a multisystem disorder, the company said Monday. The E
REGULATION | Jul 13, 2026, 01:04 PM UTC
L
Niagen Bioscience launches pharmaceutical program for aging and genetic diseases
Niagen Bioscience formally launched the first drug candidate of NAD Pharmaceuticals, its wholly owned subsidiary focused on developing therapies for accelerated aging and rare genetic diseases. The program will primarily
EQUITY | Jul 08, 2026, 12:39 PM UTC